IGC - Latest News

IGC Pharma, Inc. (IGC), operates in Healthcare / Biotechnology, trades on AMEX.

Market capitalization stands near $26.5M. Beta to the broader market is 0.48.

The article list below shows the most recent IGC headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent IGC Headlines

IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment

accessnewswire.com - Oct 13, 2026

POTOMAC, MD / ACCESS Newswire / October 13, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology comp

IGC Pharma, Inc. (NYSEAMERICAN:IGC) Stock Short Interest Jumps 48.0%

defenseworld.net - Oct 3, 2026

IGC Pharma, Inc. (NYSEAMERICAN:IGC - Get Free Report) was the recipient of a large increase in short interest during the month of September.

IGC Pharma Completes Enrollment in Phase 2 CALMA Alzheimer's Trial; Topline Results Expected Q4 2026

accessnewswire.com - Sep 28, 2026

POTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced it has completed e

IGC Pharma Reports Q2 2026 Results as CALMA Alzheimer's Trial Moves Within Six Randomizations of Enrollment Closure

accessnewswire.com - Aug 17, 2026

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026

IGC Pharma Strengthens Regulatory Readiness as Phase 2 CALMA Alzheimer's Trial Approaches Enrollment Closure and Q4 Topline Readout

accessnewswire.com - Aug 11, 2026

POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology compa

How News Affects IGC Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track IGC's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked IGC news questions

What is the latest IGC news headline?

The most recent IGC headline (Oct 13, 2026) is "IGC Pharma Unveils PRISM AI Platform to Move Alzheimer's Risk Prediction to Brain-Health Action and Commercial Deployment". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the IGC news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What IGC news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual IGC options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.